Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

BACKGROUND: Advanced renal cell carcinoma (RCC) has a very dismal prognosis. Cabozantinib, a tyrosine kinase inhibitor, has been approved for the treatment of advanced RCC. However, the impact of cabozantinib on the immune microenvironment of RCC remains poorly understood. METHODS: Kaplan-Meier surv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Liu, Hongyan, Sun, Shishuo, Wang, Gang, Lu, Mengmeng, Zhang, Xiaokang, Wei, Xiaohuan, Gao, Xiaoge, Huang, Chao, Li, Zhen, Zheng, Junnian, Zhang, Qing
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089383/
https://ncbi.nlm.nih.gov/pubmed/33954115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.663517
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados